Avinash Kumar, Ph.D.
Research Scientist, Cancer Research laboratories/Dr. Levenson Lab Director, Small Animal Imaging Core
Avinash.Kumar@liu.edu
(718) 780-6061
Ph.D., National Chemical Laboratory, University of Pune, Pune, INDIA
DBT-Postdoctoral Fellow, National Center for Cell Science, Pune, INDIA
Postdoc Research Fellow, Cancer Institute, University of Mississippi Medical Center (UMMC), Jackson, MS
Dr. Kumar received his Ph.D. in protein biochemistry and biophysics in 2012, after which he was awarded the postdoctoral fellowship from Department of Biotechnology (DBT), Govt. of India to carry out his research on cancer biology and epigenetics. After completion of this fellowship Dr. Kumar worked as a postdoc research fellow at the Cancer Institute, UMMC from 2013-16. Only recently, he joined Long Island University, College of Pharmacy and Health Sciences as a Research Scientist for Cancer Research Laboratories and Director of the Small Animal Imaging core. For the past three years Dr. Kumar’s research has focused on understanding the role and regulation of metastasis-associated protein 1 (MTA1), a chromatin modifier, in prostate cancer biology and on utilization of dietary stilbenes, such as resveratrol and pterostilbene among others as MTA1 inhibitors for prostate cancer chemoprevention and treatment. Dr. Kumar is an ad-hoc as well as an active reviewer for some journals. He is the author of 11 peer-reviewed publications, two book chapters and 17 abstracts. Dr. Kumar is an associate member of the American Association for Cancer Research (AACR).
MTA1 has been shown to play a critical role in prostate cancer progression and metastasis by inhibiting apoptosis and promoting angiogenesis. There is also available evidence that MTA1 can serve as an independent prognostic marker for aggressive prostate cancer, particularly in African American men. We have shown that MTA1 is involved in post-translational deacetylation of PTEN leading to inactivation of its tumor suppressor functions and hyperactivation of pAkt survival pathway. Using prostate specific Pten-null and Pten-haploinsufficient model, we have shown that MTA1 is a key regulator of prostate cancer initiation and progression by inducing inflammation and epithelial-mesenchymal transition (EMT). Currently, we aim to further our understanding of MTA1-mediated genetic and epigenetic mechanisms in prostate cancer progression and metastasis. In addition, we have also showed the MTA1 and miRNA targeting capabilities of dietary stilbenes (e.g. resveratrol and pterostilbene). Currently, we aim to understand the MTA1-targeted efficacy of these agents in combination with already approved FDA chemotherapeutic drugs in the treatment of prostate cancer.
Join the LIU Community!
We can't wait to welcome you to Shark Nation.
The application process is quick and easy, but if you have
any questions, our admissions counselors are here to help.
Apply Now!
© Long Island University
1 University Plaza, Brooklyn, New York 11201-5372
CONTACT
LIU Pharmacy
Arash T. Dabestani
PharmD, MHA, FASHP, FABC
Dean
718-488-1004
EXPLORE
LIU Brooklyn Campus Life
Scholarships & Financial Aid
Enrollment Services
ADMISSIONS
718-488-1011
bkln-enroll@liu.edu